Durable remission of C3 glomerulonephritis with mycophenolate mofetil.
In C3 glomerulopathy, uncontrolled complement C3 activation via the alternative pathway results in glomerular C3 deposition and, in many cases, progressive renal failure. Despite advances in understanding of C3G pathogenesis over the last few years, there are no proven treatments. We describe a patient in whom C3 glomerulopathy was associated with renal impairment and elevated serum free kappa light chains. An initial response to corticosteroids was followed by relapse once steroids were weaned, prompting use of mycophenolate mofetil to maintain remission. We discuss some of the diagnostic and therapeutic issues surrounding C3G, including in the setting of monoclonal gammopathy.
Department of Nephrology, The Royal Melbourne Hospital, Victoria, Australia.
Nicole
N
Lioufas
Department of Anatomical Pathology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Moira
M
Finlay
Department of Nephrology, The Royal Melbourne Hospital, Victoria, Australia.
Thomas
T
Barbour
D003176:Complement C3; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005921:Glomerulonephritis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000627:therapeutic use*; D010265:Paraproteinemias / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012074:Remission Induction
D003176:Complement C3; D004791:Enzyme Inhibitors; D009173:Mycophenolic Acid